New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 5.71mg equivalent to 5 mg atomoxetine free base - capsule - 5 mg - active: atomoxetine hydrochloride 5.71mg equivalent to 5 mg atomoxetine free base excipient: dimeticone gelatin iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 68.56mg equivalent to 60 mg atomoxetine free base - capsule - 60 mg - active: atomoxetine hydrochloride 68.56mg equivalent to 60 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 91.42mg equivalent to 80 mg atomoxetine free base - capsule - 80 mg - active: atomoxetine hydrochloride 91.42mg equivalent to 80 mg atomoxetine free base excipient: dimeticone gelatin   iron oxide red iron oxide yellow pregelatinised maize starch sodium laurilsulfate   tekprint black sw-9008   tekprint black sw-9010   titanium dioxide   - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - raloxifene hydrochloride 60mg equivalent to 55.7 mg raloxifene free base - film coated tablet - 60 mg - active: raloxifene hydrochloride 60mg equivalent to 55.7 mg raloxifene free base excipient: carnauba wax crospovidone lactose lactose monohydrate magnesium stearate opacode blue s-1-10537g opadry white ys-1-18027-a polysorbate 80 povidone

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml;   - solution for injection - 100 u/ml - active: insulin lispro 100 u/ml   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml;   - solution for injection - 100 u/ml - active: insulin lispro 100 u/ml   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol sodium hydroxide water zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; 0-3% overage) - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; 0-3% overage) excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg - dispersible tablet - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg excipient: aniseed colloidal silicon dioxide crospovidone mannitol mentha x piperita microcrystalline cellulose saccharin sodium sodium stearyl fumarate sorbitol starch - depression and it's associated anxiety, bulimia nervosa, obsessive-compulsive disorder and premenstrual dysphoric disorder - a severe form of pms. diagnosis of pmdd: the essential features of pmdd are clear and established cyclicity of symptoms (occurring during the last week of the luteal phase in most menstrual cycles) such as depressed mood, anxiety, affective lability, and physical symptoms such as breast tenderness or swelling, headaches, joint or muscle pain, bloating, and weight gain. pmdd is a severe clinical entity and is distinguished from the broader premenstrual syndrome by the intensity of its symptoms (particularly mood symptoms) and the extent to which it interferes with social and/or occupational function